Navigation Links
Despite its Weak Pipeline, Schizophrenia Market May Benefit from Drugs Used in Similar Indications, Says GBI Research
Date:4/12/2016

LONDON, April 12, 2016 /PRNewswire/ --

A new report from business intelligence provider GBI Research - Frontier Pharma: Schizophrenia and Associated Indications - states that although the schizophrenia market is replete with unmet needs and its pipeline is paltry, the overall level of innovation for schizophrenia-related indications - which comprise depression, panic disorders, obsessive compulsive disorder, post-traumatic stress disorder and cognitive deficit - is far higher, and has the potential to provide some benefit to patients with schizophrenia.

The large population of schizophrenia patients in relation to its small pipeline of 134 products is indicative of a low level of investment in Research and Development (R&D), most likely due to a poor understanding of the underlying disease mechanisms. This acts as a strong barrier to the development of effective pharmaceutical products.

Managing Analyst Dominic Trewartha explains: "While current treatments offer some relief from symptoms such as hallucinations, they have not proven as effective for cognitive dysfunction and symptoms such as the inability to feel pleasure, and there are no disease-modifying drugs currently available. A number of combinations, such as the addition of adjuvant agents to antipsychotic medication, have been trialed, but they have had little impact."

GBI Research states that there are 360 products in the pipeline for conditions associated with schizophrenia, 60 of which are first-in-class, equating to 21% of products with a disclosed molecular target. Overall, while the proportion of first-in-class products is still low, there are more in the pipeline for schizophrenia-related indications, particularly depressions and cognitive deficit, than there are for schizophrenia itself, and these act across a far wider range of molecular targets.

Trewartha continues: "The range of innovation is relatively diverse in the pipelines for schizophrenia and related indications, with products acting on numerous novel molecular targets, including D-Amino Acid Oxidase, glutamate carboxypeptidase 2, and a number of probable G protein-coupled receptors.

"It is likely that small molecules will remain clinically and commercially the most successful molecule types across many therapy areas and indications, being particularly relevant in the central nervous system (CNS) and schizophrenia, with only limited prospects that new product approvals could change the landscape.

"Despite industry-wide trends towards a diversification in therapeutic molecule types, it is unlikely that this will be translated in CNS disorders and schizophrenia, due to the challenges of crossing the blood-brain barrier with larger and more complex molecular types."

Sample pages of GBI Research's report Frontier Pharma: Schizophrenia and Associated Indications are available upon request

About GBI Research 

GBI Research is a leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key healthcare industry influencers to ensure you stay up-to-date with the latest market trends. For more information about our offerings, please contact us on:

+44(0)161-359-5817 

Connect with GBI Research on social media for the latest healthcare market updates:

Facebook | LinkedIn | Twitter



'/>"/>
SOURCE GBI Research
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Despite the Numerous Agents in Development for the Treatment of Chronic HCV Infections, a Notable Share of Physicians in Europe Lack Awareness of the HCV Pipeline
2. ResearchMoz.us: Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity
3. Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity
4. Despite A Difficult Competitive Environment, Opportunities Can Still Be Found In The Growing US Trauma Fixation Device Market
5. Despite Increasing Cost Sensitivity of EU5 Payers, Sofosbuvir and Simeprevir are Poised to Reshape the Hepatitis C Virus Market by End of 2015
6. ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations
7. Power Morcellator Critic Vows to Carry On Despite Threat of Legal Action, Bernstein Liebhard LLP Reports
8. Despite Its Limited Size, Chiles Pharmaceutical Market Offers Growing Opportunity for Drug Industry
9. Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 - Off-patent Chemo-regimens to Retain Dominance Despite New Launches
10. Asia-Pacific Rheumatoid Arthritis Therapeutics Markets 2015-2021 - Novel IL-6 and JAK Inhibitors to Stimulate Moderate Growth Despite Brand Erosion of Blockbuster Anti-TNFs
11. Despite Push for Transparent Medical Records, 53% of Consumers Cant Access Electronic Health Data, HealthMine Survey Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... founder of Echenberg Institute, is announcing a new safe and effective at-home ... and other painful pelvic pain conditions such as pelvic floor dysfunction, vulvodynia, ... ... ... start-up company, VuVatech LLC, fills a void in the women,s wellness market ...
(Date:7/10/2017)... 10, 2017  The tenth annual BioPharm America™ ... at the Sheraton Boston Hotel, September 26–27. ... to global decision makers and innovative biotech startup companies. ... leaders during two impactful days. BioPharm America is now ... additional networking opportunities with 4,500+ life science industry influencers ...
Breaking Medicine Technology:
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... ... autologous fat (adipose) transfer systems announces the issuance of United States Patent Number ... for its adipose filtration technology. The '398 and '324 patents cover methods ...
(Date:7/24/2017)... ... July 24, 2017 , ... Paul Vitenas, MD, FACS is excited to ... surgeons, invited to attend Allergan’s recent meeting with their Plastics Advisory Board. As one ... world, Allergan is bringing a newly defined structure to the aesthetics market. Dr. ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... ... **Presented by FDAnews and MSceppa Consulting **, Aug. 22-23, 2017 – Arlington, VA, ... Friday, July 28. , Increased FDA scrutiny and growing demands to track and ...
(Date:7/24/2017)... , ... July 24, 2017 , ... “Nana Nana Boo ... importance of being kind to others. “Nana Nana Boo Boo” is the creation of ... man. , Published by Christian Faith Publishing, Michael Rush’s new book presents the ...
(Date:7/23/2017)... ... July 23, 2017 , ... ... provider of education and training standards for healthcare treatment providers, offers healthcare ... Certification: the iaedp™ Core Curriculum. , Presented as either online or as ...
Breaking Medicine News(10 mins):